IceCure Medical Ltd. - Ordinary Shares (ICCM)

1.4800Last Price

0.00 (0.00%)Change

Icecure Medical Ltd is a pioneering medical technology company that specializes in the development and commercialization of innovative treatments for cancer using its proprietary cryoablation technology

This minimally invasive approach involves the use of extreme cold to target and destroy cancerous cells while preserving surrounding healthy tissue. The company focuses on providing effective solutions for a range of tumors, positioning its products to improve patient outcomes and enhance the overall experience of cancer treatment. Through ongoing research and collaboration with healthcare professionals, Icecure aims to advance the field of oncology and offer patients safer, less invasive alternatives to traditional therapies.

IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

CAESAREA, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares, to maintain a minimum bid price of $1.00 per share.

By IceCure Medical Ltd. · Via GlobeNewswire · January 12, 2024